A randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of Ad5FGF-4 in female patients with stable angina pectoris who are not candidates for revascularization.

Trial Profile

A randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the efficacy and safety of Ad5FGF-4 in female patients with stable angina pectoris who are not candidates for revascularization.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2012

At a glance

  • Drugs Alferminogene-tadenovec (Primary)
  • Indications Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARE
  • Most Recent Events

    • 07 Jun 2011 Planned end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 16 Nov 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
    • 14 Mar 2008 This trial is expected to be completed in 2009, according to a media release dated 14/3/08 [htt://www.cardiumthx.com].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top